GANJ’s Dr. Grossman Leads the Charge for Genomic Analysis of GI Malignancies

Our efforts to consistently search for revolutionary ideas, procedures, and treatments have reached an all-time high. Dr. Grossman leads the charge as Gastroenterology Associates of New Jersey (GANJ) initiates a program for full genomic analysis of all gastrointestinal (GI) malignancies encountered in a hospital setting.

“This is a truly revolutionary step in cancer care to our patient population, and we are already seeing positive results,” states Dr. Grossman in a statement to his GANJ colleagues.

Every cancer—like every patient—is different. A genomic tumor assessment can help identify the DNA alterations that are driving the growth of a particular tumor. Not only can this revolutionary testing help determine the cause, but specific treatment plans are based on the unique results in individual patients, as well.

Always remember: Genetic testing is voluntary and, although it has many benefits, limitations and risks also exist. Don’t hesitate to speak with your gastroenterologist about possible genomic testing, and be sure to ask for the benefits and risks and how they apply to you.